Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells

Biomedical Research

Volumn 30, Issue 1, 2009, Pages 7-15

  Narita, Yoshinori ^a   Wakita, Daiko ^a   Ohkuri, Takayuki ^a   Chamoto, Kenji ^a   Nishimura, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; CD11B ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; MACROPHAGE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; SPLEEN; SPLENOMEGALY; SUPPRESSOR CELL; TH1 CELL; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR VOLUME; FEMALE; IMMUNE DEFICIENCY; INTERFERON PRODUCTION;

MUS;

ANIMALS; ANTIGENS, CD11B; CELL DIFFERENTIATION; CELL LINE, TUMOR; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-3; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYELOID CELLS; RECEPTORS, CHEMOKINE; SPLEEN; TH1 CELLS;

EID: 66749149867     PISSN: 0970938X     EISSN: None     Source Type: Journal    
DOI: 10.2220/biomedres.30.7     Document Type: Article

References (31)

1. Bronte V and Zanovello P (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5, 641-654.
2. Bunt SK, Yang L, Sinha P, Clements VK, Leips J and Ostrand-Rosenberg S (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67, 10019-10026.
3. Chamoto K, Wakita D, Narita Y, Zhang Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H and Nishimura T (2006) An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy. Cancer Res 66, 1809-1817.
4. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, Mc-Grady G and Wahl SM (2003) Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198, 1875-1886.
5. Gabrilovich D (2004) Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4, 941-952.
6. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S and Schreiber H (2007) The terminology issue for myeloid-derived suppressor cells. Cancer Res 67, 425.
7. Gabrilovich D, Velders MP, Sotomayor EM and Kast WM (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 166, 5398-5406.
8. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S and Carbone DP (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150-4166.
9. Huang B, Pan PY, Li Q, Sato AI, Levy DDE, Bromberg J, Divino CM and Chen SH (2007) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66, 1123-1131.
10. Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T and Nishimura T (2004) The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 95, 697-703.
11. Kao JY, Gong Y, Zheng QD and Chen JJ (2003) Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol 170, 3806-3811.
12. Kim R, Emi M, Tanabe K and Arihiro K (2006) Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66, 5527-5536.
13. Kusmartsev S and Gabrilovich DI (2005) Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 55, 237-245.
14. Kusmartsev S and Gabrilovich DI (2005) STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 174, 4880-4891.
15. Kusmartsev S, Nefedova Y, Yoder D and Gabrilovich DI (2004) Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172, 989-999.
16. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, Thompson S, Chen X, Andreansky S and Katsanis E (2006) Tumor-derived CD4 (+) CD25 (+) regulatory T cell suppression of dendritic cell function involves TGFbeta and IL-10. Cancer Immunol Immunother 56, 48-59.
17. Li Q, Pan PY, Gu P, Xu D and Chen SH (2004) Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res 64, 1130-1139.
18. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA and Le C (2007) Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178, 2883-2892.
19. Melani C, Chiodoni C, Forni G and Colombo MP (2003) Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102, 2138-2145.
20. Mellman I and Steinman RM (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255-258.
21. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J and Gabrilovich D (2007) Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 13, 828-35.
22. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M and Ohta A (1999) Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190, 617-627.
23. Sato M, Chamoto K and Nishimura T (2003) A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th1 cells. Int Immunol 15, 837-843.
24. Serafini P, Carbley R, Noonan NA, Tan G, Bronte V and Borrello I (2004) High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64, 6337-6343.
25. Sica A and Bronte V (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117, 1155-1166.
26. Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S, Dinarello CA, Voronov E and Apte RN (2005) CD11b+Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol 175, 8200-8208.
27. Steinman RM and Pope M (2002) Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109, 1519-1526.
28. Suzuki Y, Wakita D, Chamoto K, Narita Y, Tsuji T, Takeshima T, Gyobu H, Kawarada Y, Kondo S, Akira S, Katoh H, Ikeda H and Nishimura T (2004) Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res 64, 8754-8760.
29. Wakita D, Chamoto K, Zhang Y, Narita Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H and Nishimura T (2006) An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. Int Immunol 18, 425-434.
30. Yang AS and Lattime EC (2003) Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 63, 2150-2157.
31. Yang Y, Cai Z, Zhang Y, Yutzy WH, Roby KF and Roden RBS (2006) CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+ CD11b+ myeloid cells. Cancer Res 66, 6807-6815.